Skip to main content

Market Overview

Exelixis' Cabozantinib Gets Breakthrough Therapy Status In Differentiated Thyroid Cancer

  • The FDA has granted Breakthrough Therapy Designation to Exelixis Inc's (NASDAQ: EXEL) CABOMETYX cabozantinib as a potential treatment for patients with differentiated thyroid cancer progressed following prior therapy and are radioactive iodine-refractory.
  • The company plans to submit a supplemental marketing application for the indication this year.
  • The planned interim analysis of the Phase 3 COSMIC-311 trial demonstrated a significant reduction in the risk of disease progression or death of 78% with cabozantinib versus placebo, thyroid cancer.
  • Price Action: EXEL shares are down 1.85% at $22.24 on the last check Thursday.

Related Articles (EXEL)

View Comments and Join the Discussion!

Posted-In: FDA Breakthrough Designation Thyroid CancerBiotech News FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at